[Development and prospect of tissue engineering in urology].


Journal

Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi
ISSN: 1001-5515
Titre abrégé: Sheng Wu Yi Xue Gong Cheng Xue Za Zhi
Pays: China
ID NLM: 9426398

Informations de publication

Date de publication:
25 Apr 2020
Historique:
entrez: 25 4 2020
pubmed: 25 4 2020
medline: 13 8 2020
Statut: ppublish

Résumé

Tissue engineering technology and stem cell research based on tissue engineering have made great progresses in overcoming the problems of tissue and organ damage, functional loss and surgical complications. Traditional method is to use biological substitute materials to repair tissues, while tissue engineering technology focuses on combining seed cells with biological materials to form biological tissues with the same structure and function as its own to repair tissue defects. The advantage is that such tissue engineering organs and tissues can solve the problem that the donor material is limited, and effectively reduce complications. The purpose of tissue engineering is to find suitable seed cells and biomaterials which can replace the biological function of original tissue and build suitable microenvironment 基于组织工程学的组织工程技术和干细胞研究在克服组织器官损伤、修复组织器官功能缺失及减少手术并发症等问题上现已取得很大进展。以往传统方法是利用生物替代材料修复组织,而组织工程技术注重将种子细胞与生物材料结合,形成与自身组织结构和功能相同的生物组织来修复组织缺损,优势在于通过组织工程技术可克服供体材料获取的局限性,并能有效减少并发症。组织工程技术的研究目的便是找到最终能很好替代原有组织生物学功能的合适的种子细胞、生物材料,构建适合的体内微环境。本文主要描述目前泌尿外科学中各领域组织工程的发展现状,探讨组织工程技术应用于治疗复杂泌尿系统疾病的未来趋势。本文研究结果显示,尽管目前临床试验还相对较少,但现有研究在动物模型上取得的良好结果揭示了组织工程技术今后用于治疗各种泌尿系统疾病的光明前景。.

Autres résumés

Type: Publisher (chi)
基于组织工程学的组织工程技术和干细胞研究在克服组织器官损伤、修复组织器官功能缺失及减少手术并发症等问题上现已取得很大进展。以往传统方法是利用生物替代材料修复组织,而组织工程技术注重将种子细胞与生物材料结合,形成与自身组织结构和功能相同的生物组织来修复组织缺损,优势在于通过组织工程技术可克服供体材料获取的局限性,并能有效减少并发症。组织工程技术的研究目的便是找到最终能很好替代原有组织生物学功能的合适的种子细胞、生物材料,构建适合的体内微环境。本文主要描述目前泌尿外科学中各领域组织工程的发展现状,探讨组织工程技术应用于治疗复杂泌尿系统疾病的未来趋势。本文研究结果显示,尽管目前临床试验还相对较少,但现有研究在动物模型上取得的良好结果揭示了组织工程技术今后用于治疗各种泌尿系统疾病的光明前景。.

Identifiants

pubmed: 32329268
doi: 10.7507/1001-5515.201910058
pmc: PMC9927608
doi:

Substances chimiques

Biocompatible Materials 0

Types de publication

Journal Article Review

Langues

chi

Sous-ensembles de citation

IM

Pagination

193-199

Références

Biochem Biophys Res Commun. 2019 Oct 8;518(1):141-147
pubmed: 31420163
Curr Opin Hematol. 2016 May;23(3):253-9
pubmed: 27055047
Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4003-8
pubmed: 23431178
Biomaterials. 2014 Jan;35(1):105-12
pubmed: 24140043
Methods. 2016 Apr 15;99:112-9
pubmed: 26134528
Sci Rep. 2017 Feb 06;7:41934
pubmed: 28165009
Tissue Eng Part B Rev. 2019 Jun;25(3):202-224
pubmed: 30648478
J Pediatr Urol. 2011 Jun;7(3):276-82
pubmed: 21527232
Tissue Eng Part A. 2020 Jan;26(1-2):78-92
pubmed: 31238789
Lancet. 2006 Apr 15;367(9518):1241-6
pubmed: 16631879
Adv Healthc Mater. 2014 May;3(5):628-41
pubmed: 24443420
Tissue Eng Part A. 2012 May;18(9-10):1025-34
pubmed: 22136657
Tissue Eng Part B Rev. 2014 Apr;20(2):163-72
pubmed: 23895225
J Surg Res. 2012 Nov;178(1):55-62
pubmed: 22482758
Tissue Eng Regen Med. 2019 Jun 22;16(5):501-512
pubmed: 31624705
J Urol. 2011 Nov;186(5):2014-20
pubmed: 21944117
Stem Cell Res Ther. 2014 May 28;5(3):69
pubmed: 25157812
Mater Sci Eng C Mater Biol Appl. 2019 Sep;102:228-237
pubmed: 31146995
Lancet. 2011 Apr 2;377(9772):1175-82
pubmed: 21388673
Trends Biotechnol. 2016 Jun;34(6):470-482
pubmed: 27138899
Nat Med. 2013 May;19(5):646-51
pubmed: 23584091
Biomaterials. 2013 Aug;34(24):5915-25
pubmed: 23680364
J Negat Results Biomed. 2014 Nov 08;13:17
pubmed: 25381044
Front Bioeng Biotechnol. 2015 Jun 23;3:89
pubmed: 26157796
J Surg Res. 2013 Jun 15;182(2):185-91
pubmed: 23140788
Genes Dis. 2014 Sep 1;1(1):8-17
pubmed: 25411659
Acta Biomater. 2017 Mar 1;50:154-164
pubmed: 27940192
Adv Drug Deliv Rev. 2015 Mar;82-83:31-7
pubmed: 25446136
Trends Mol Med. 2016 Mar;22(3):254-265
pubmed: 26856235
Mater Sci Eng C Mater Biol Appl. 2017 Jun 1;75:877-884
pubmed: 28415542
Biotechnol Lett. 2014 Sep;36(9):1909-16
pubmed: 24930094

Auteurs

Ming Yang (M)

Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, P.R. China.

Qiang Fu (Q)

Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, P.R. China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH